<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358367</url>
  </required_header>
  <id_info>
    <org_study_id>01041620</org_study_id>
    <nct_id>NCT04358367</nct_id>
  </id_info>
  <brief_title>Intravenous Dexmedetomidine in Cesarean Section Under Spinal Anesthesia</brief_title>
  <official_title>Intravenous Dexmedetomidine Reduces Hypotension and Epigastric Pain in Cesarean Section Under Spinal Anesthesia: A Randomized Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Egyptian Biomedical Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Egyptian Biomedical Research Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study hypothesized that intravenous dexmedetomidine use during spinal anesthesia
      for cesarean section has a beneficial influence on hemodynamic stability and epigastric pain
      together with satisfactory analgesic effects and excellent safety profile for the mother and
      the newborn.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and aim: Hypotension and epigastric pain are commonly encountered during spinal
      anesthesia for cesarean section. Dexmedetomidine (DEX) is a highly selective α 2-adrenergic
      agonist. Its effects entail sympatholytic, sedative, anesthetic, and analgesic actions. The
      present randomized study aimed to evaluate the effect of intravenous DEX administration on
      the hemodynamic parameters and epigastric pain in women subjected to cesarean section.

      Patients and Methods: This study is a randomized double-blinded controlled trial. Seventy
      patients were randomly assigned to one of two interventional groups: one group received
      spinal anesthesia and intravenous DEX (1µg/kg) and the other group received spinal anesthesia
      and placebo (saline). The administrated drugs were slowly injected intravenously over 10
      minutes then intrathecal block was achieved using 2-2.2 ml of hyperbaric bupivacaine (10
      -12.5 mg) introduced at L3/4 or L4/5 interspace. Primary Outcome parameters included
      frequency of hypotension episodes, frequency of ephedrine doses needed, sedation score and
      epigastric pain episodes. Secondary outcomes included time to onset of sensory and motor
      blocks, duration of sensory and motor blocks, operative duration, time needed to request of
      rescue analgesia, level of intrathecal block, and neonatal Apgar score at 1 and 5 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 19, 2019</start_date>
  <completion_date type="Actual">November 19, 2019</completion_date>
  <primary_completion_date type="Actual">October 19, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hypotension</measure>
    <time_frame>up to 48 hours postoperative</time_frame>
    <description>systolic blood pressure &lt; 90 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ephedrine use</measure>
    <time_frame>up to 48 hours postoperative</time_frame>
    <description>frequency of ephedrine doses needed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sedation</measure>
    <time_frame>up to 48 hours postoperative</time_frame>
    <description>sedation score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>epigastric pain</measure>
    <time_frame>up to 48 hours postoperative</time_frame>
    <description>Pain in the epigastric region assessed by Visual Analog Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sensory and motor blocks</measure>
    <time_frame>Intraoperative</time_frame>
    <description>time to onset of sensory and motor blocks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Cesarean Section Complications</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>spinal anesthesia and intravenous dexmedetomidine(1µg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>spinal anesthesia and placebo (saline).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Injectable Product</intervention_name>
    <description>Spinal anesthesia and intravenous dexmedetomidine (1μg/kg). The administrated drugs were slowly injected intravenously over 10 minutes then intrathecal block was achieved using 2-2.2 ml of hyperbaric bupivacaine (10 -12.5 mg) introduced at L3/4 or L4/5 interspace.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Spinal anesthesia and intravenous saline. The administrated drugs were slowly injected intravenously over 10 minutes then intrathecal block was achieved using 2-2.2 ml of hyperbaric bupivacaine (10 -12.5 mg) introduced at L3/4 or L4/5 interspace.</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Full-term pregnancy and American Society of Anesthesiologists (ASA) physical status
             I/II in women scheduled for elective cesarean section

        Exclusion Criteria:

          -  Severe hepatic or renal disease

          -  Severe cardiopulmonary disease

          -  Thyroid disorders multiple allergies prematurity

          -  Known fatal abnormality

          -  Known chronic gastrointestinal problems with epigastric pain e.g. peptic ulcer and
             reflux esophagitis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Elsawy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Al-Azhar University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Al-Azhar University Faculty of Medicine</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>spinal anesthesia</keyword>
  <keyword>cesarean section</keyword>
  <keyword>epigastric pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

